4D Molecular Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2019 | $-36.7M | $-39.9M | $3.2M | $3.5M |
| FY2020 | $-50.9M | $-51.9M | $1.0M | $5.0M |
| FY2021 | $-69.1M | $-78.2M | $9.1M | $13.8M |
| FY2022 | $-86.7M | $-98.2M | $11.5M | $17.1M |
| FY2023 | $-75.8M | $-78.6M | $2.8M | $19.7M |
| FY2024 | $-134.6M | $-138.4M | $3.8M | $26.1M |
| FY2025 | $-109.1M | $-109.6M | $536.0K | $22.0M |